GSK
GlaxoSmithKline PLC
49.50$
-1.8%
vs. previous close
Closing price · As of: Aug 14, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 36.1% | 31.0% | 28.3% | 28.2% | 29.2% | 24.5% | 25.2% | 23.6% | 34.5% | 31.6% | 28.6% | 28.6% | |
| 10.7% | 10.9% | 8.3% | 6.8% | 6.7% | 5.9% | 7.8% | 5.4% | 6.2% | 5.0% | 6.2% | 5.6% | |
| 10.8% | 11.0% | 8.4% | 6.9% | 6.8% | 6.0% | 7.9% | 5.5% | 13.1% | 8.8% | 6.2% | 5.6% | |
| 11.0% | 7.3% | 10.0% | 10.6% | 10.9% | 9.0% | 9.0% | 10.2% | 10.3% | 12.5% | 10.1% | 12.7% | |
| 10.4% | 8.8% | 8.6% | 9.9% | 9.4% | 7.5% | 7.5% | 7.3% | 8.6% | 9.3% | 9.5% | 9.7% | |
| 34.7% | 18.1% | 18.3% | 19.3% | 19.0% | 10.7% | 10.0% | 10.0% | 16.0% | 13.2% | 16.9% | 16.5% | |
| 9.2% | 9.7% | 10.1% | 10.2% | 10.0% | 13.3% | 13.2% | 13.3% | 11.7% | 11.5% | 11.7% | 11.5% | |
| 20.5% | 31.2% | 31.8% | 31.1% | 29.6% | 38.8% | 37.1% | 38.0% | 23.8% | 25.0% | 26.1% | 27.4% | |
| 87.9% | 83.4% | 91.6% | 93.8% | 93.7% | 77.0% | 74.1% | 73.0% | 83.2% | 78.3% | 78.0% | 73.8% | |
| 32.7% | 25.1% | 32.2% | 47.1% | 38.7% | 30.2% | 27.5% | 29.9% | 37.9% | 35.7% | 36.5% | 35.0% | |
| 7.2% | 2.4% | 7.0% | 5.0% | 10.0% | 8.7% | 4.6% | 4.6% | 6.6% | 4.8% | 4.0% | 4.9% | |
| 19.6% | 17.2% | 20.3% | 37.2% | 6.3% | 5.2% | 5.4% | 5.7% | 6.4% | 6.3% | 5.8% | 25.2% | |
| 60.7% | 28.6% | 24.7% | 25.2% | 34.8% | 21.4% | 21.3% | 19.2% | 28.3% | 18.8% | 23.0% | 23.0% | |
| 12.1% | 16.6% | 8.4% | 6.2% | 6.5% | 14.3% | 18.1% | 19.0% | 17.6% | 22.6% | 23.0% | 26.8% | |
| -5.1% | -2.6% | -9.1% | -11.5% | -4.7% | 8.0% | 10.7% | 12.4% | 7.3% | 12.3% | 13.1% | 16.7% | |
| 4.8% | 3.7% | 3.3% | 3.5% | 3.4% | 1.9% | 1.8% | 1.5% | 3.4% | 2.7% | 3.5% | 3.4% |
Data as of: August 14, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.